More on Sanofi-Aventis Bristol Myers Squibb Potential Merger
Seems the Sanofi BMS merger talks haven’t been without some truth to them. Now the Times Online is reporting that there is a split on the Sanofi side over strategy
The Times has learnt that a disagreement over strategy has emerged between Jean-François Dehecq, the Sanofi chairman, who favours a transformational deal with BMS, and Gérard Le Fur, his younger chief executive, who has emphasised the need to focus on the group’s internal drug research and development programme.
The article goes on to say that the former view of merger with transformation is more probable. I think that it might be the less attractive strategy in the long run. I’m not a big fan of mergers since few ever really show the advantages that are promised.
I think the continuing trend of mega-mergers in the pharmaceutical industry will continue but I also do not think it will solve the long terms problems of the industry.
Technorati Tags: BMS, Bristol-Myers Squibb, pharma M&A, pharmaceutical deals, Sanofi-Aventis
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
